Eamonn Mcaleese
About Eamonn Mcaleese
Eamonn Mcaleese is a Downstream Bioprocess Associate at Bristol-Myers Squibb with over five years of experience in the biopharmaceutical industry.
Current Role at Bristol-Myers Squibb
Eamonn Mcaleese is presently employed at Bristol-Myers Squibb as a Downstream Bioprocess Associate. In this capacity since July 2018, he is responsible for the purification and formulation of biopharmaceutical products. His role involves various downstream bioprocessing tasks critical for the production of therapeutics.
Previous Experience in Bioprocessing
Before joining Bristol-Myers Squibb, Eamonn Mcaleese worked at Bio Products Laboratory Limited as a Downstream Production Technician from 2016 to 2018. His responsibilities included various aspects of downstream processing essential for biopharmaceutical product development. He also undertook a placement at NIBRT (National Institute for Bioprocessing Research and Training) from 2015 to 2016, gaining valuable hands-on experience in the field.
Experience in the Retail Sector
Apart from his biopharmaceutical career, Eamonn Mcaleese also worked in the retail sector. He was a Stockroom Manager at AllSaints Retail Ltd from 2014 to 2015 for a duration of 9 months. This role likely provided him with varied skills in inventory management and logistics.
Education and Academic Background
Eamonn Mcaleese has a solid academic foundation in bioprocessing and related fields. He studied at the Institute of Technology, Tallaght from 2015 to 2016. Prior to this, he completed his Bachelor's degree in Science from University College Dublin, where he studied from 2008 to 2014. This combination of academic and practical training has equipped him well for his roles in the biopharmaceutical industry.
Expertise in Downstream Bioprocessing
Eamonn Mcaleese is well-versed in downstream bioprocessing, a critical phase in biopharmaceutical production involving purification and formulation of products. Over his more than five years in the industry, he has developed a specialization in these processes, ensuring high-quality outcomes for biopharmaceutical products.